Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Assets (2017 - 2026)

Denali Therapeutics has reported Assets over the past 9 years, most recently at $1.1 billion for Q4 2025.

  • Quarterly Assets fell 16.69% to $1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, down 16.69% year-over-year, with the annual reading at $1.1 billion for FY2025, 16.69% down from the prior year.
  • Assets was $1.1 billion for Q4 2025 at Denali Therapeutics, up from $1.1 billion in the prior quarter.
  • Over five years, Assets peaked at $1.6 billion in Q1 2024 and troughed at $1.1 billion in Q3 2025.
  • The 5-year median for Assets is $1.3 billion (2022), against an average of $1.3 billion.
  • Year-over-year, Assets soared 133.23% in 2021 and then decreased 27.4% in 2025.
  • A 5-year view of Assets shows it stood at $1.4 billion in 2021, then increased by 3.99% to $1.5 billion in 2022, then fell by 20.98% to $1.2 billion in 2023, then grew by 19.09% to $1.4 billion in 2024, then dropped by 16.69% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Assets are $1.1 billion (Q4 2025), $1.1 billion (Q3 2025), and $1.2 billion (Q2 2025).